Novasep Commissions High-Potency Manufacturing Plant Expansion
Novasep reports that its EUR 4 million ($5.5 million) investment to expand its highly potent active pharmaceutical ingredients (HPAPI) manufacturing capabilities at its facility in Le Mans, France, has been completed The plant expansion has been fully qualified and is now being used to scale up validation of a commercial antibody drug conjugate (ADC) payload.
The Le Mans production facility combines chemical and purification capabilities to manufacture ADC payloads at commercial scale with an occupational exposure limit lower than 30 ng/m3 at multi-kilogram scale per batch, according to the company.
Source: Novasep
